Atopic dermatitis (endogenous eczema) is a chronic disease, the reasons for which have not yet been fully identified, but the most common ones include genetics, pharmacological factors and immunological disorders. The clinical picture varies according to age and the location of skin lesions. The disease affects babies, children and adults, and is generally characterised by skin dryness, itchiness and rashes. In addition to skin symptoms, patients can have complaints of allergic rhinitis, asthma, food allergies or allergic conjunctivitis. A combined approach, including emollients, local corticosteroids, antibiotics, anti-inflammatory medication, antihistamines and sedatives, as well as machine-assisted procedures, aims to achieve long-term prevention and control of the disease. UV treatment where the rays have a precisely defined wavelength is a good alternative for patients who are not affected by conventional treatment.

More information

It is important to be aware that atopic dermatitis and eczema are not one and the same disease. Eczema is a general name for different types of non-infectious skin inflammations that also applies to atopic dermatitis. Atopic skin has been found to have a deficit of lipids, as a result of which its protective hydrolytic barrier is impaired. This enables allergens and bacteria to penetrate more easily and provoke an inflammatory reaction, skin irritations and itchiness. The disease is the most common form of dermatitis worldwide. In cases where the standard methods of topical treatment with adrenal cortical agents do not have an effect, phototherapy is also prescribed. Exposing affected skin areas to a precisely measured quantity of UV rays helps reduce skin irritation and relieves symptoms. Clinical trials show that 70% of patients with atopic dermatitis treated with phototherapy experience lasting improvement in their condition.

DURATION

This treatment involves exposing the body to UV rays up to 4 times a week, always under medical supervision.

SUITABLE AGE

30+

APPLICATION AREAS

Full body

Methods

  • Clinical studies
  • Machine-assisted diagnostic assessments
  • Medicinal treatment
  • Specialised medical cosmetics

Recovery period

  • The combined approach is aimed at bringing the development of eczema under control and reducing the length of periods of itchiness. The aim is to provide symptom relief as quickly as possible after each procedure.

Contraindications

  • Pregnancy
  • Breastfeeding
  • Light skin
  • Rosacea
  • Severe general diseases
  • Viral and bacterial skin infections
  • Malignant skin growths
  • Pronounced hypersensitivity to UV rays
  • Diseases with proven photosensitivity

Administration

After conducting an examination and prescribing phototherapy, the specialist specifies the initial exposure dose and the total number of procedures, prepares a treatment plan personalised for each patient, with a possibility of supplementing the treatment with concomitant therapy. At each subsequent procedure, the patient’s condition is monitored by a doctor who determines the doses of exposure and takes note of any side effects and changes in therapy. The number of exposures must be at least 3 a week, with the total number of procedures normally varying between 15 and 30. If the treatments are conducted irregularly, this may affect the outcome. After the procedure, slight redness may appear in the treated area.

Frequently asked questions:

The dermatologist determines where the filler should be inserted, taking into account the patient’s anatomical features. The procedure lasts around 20-30 minutes.

The filler is spread evenly in the cheekbone area, with the results visible immediately.

No recovery period is required for this procedure. Redness or swelling may appear at the injection site, but the discomfort passes quickly (a few hours to a few days).

The effect is visible immediately and lasts around a year.

The procedure can be repeated again after the filler’s full or partial degradation.

  • Hypersensitivity to various types of fillers;
  • Skin injury at the injection site.